AlzeCure Pharma

#AlzeCure Pharma #Alzheimer's #Clinical trial

AlzeCure receives €2.5 million to advance Alzheimer’s drug 

Pharmaceutical company AlzeCure has received a €2.5 million grant from the European Innovation Council (EIC) to advance the Phase II trial of an Alzheimer’s disease treatment.  AlzeCure will advance the candidate NeuroRestore ACD856 to a Phase II trial, developed to improve patients’ learning and memory function and affect the course of disease… Read More

#Business & Investment #News

Human brain
#AlzeCure Pharma #Antidepressants #Depression #Preclinical investigations #Psychiatry

Preclinical study proves antidepressant effects of drug

The results of a preclinical study supporting the antidepressive effects of AlzeCure Pharma’s NeuroRestore ACD856 have been published in the journal Psychopharmacology. The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various… Read More

#Editor's Choice #News